HIKALNSEHikal Limited· PharmaceuticalsMinimalNeutral
Announced Thu, 28 May · 13:26 IST

Hikal Limited has informed the Exchange about Copy of Newspaper Publication

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-12.9%1-day move
₹220.99
prior close
₹209.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.2-1.9-2.0-2.9-12.9-13.2-14.8-13.3-14.4-17.8-7.0-3.1
Up moveDown movePending
AI summary

Hikal Limited has informed the exchanges about the publication of its Q4 FY26 financial results in Business Standard (English) and Mumbai Lakshadeep (Marathi) newspapers on May 28, 2026, as required under SEBI Listing Regulations. The consolidated results for Q4 FY26 show total income of ₹5,260 million, with net profit after tax of ₹144 million (EPS: ₹1.17 basic per ₹2 share). For the full year FY26, the company reported total income of ₹17,249 million but posted a net loss of ₹488 million, a significant decline from the FY25 net profit of ₹908 million, driven largely by exceptional items. The standalone figures closely mirror the consolidated ones.

Likely market impact

Hikal's full-year loss marks a sharp reversal from profitability in FY25, which may concern investors. The Q4 quarterly profit is positive but insufficient to offset the annual losses, suggesting ongoing challenges in the chemicals/pharmaceuticals business.